MedTrace Logo

Immune Response Following Seasonal Influenza Vaccination

NCT03163342 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-04-26

Study results available
· View outcomes & findings →

Summary

This is an open-label, single administration dose study in adult healthy male and female subjects. After qualifying for the study, subjects will receive a single intramuscular injection of the FDA approved 2016-2017 quadrivalent influenza vaccine.

Conditions

Interventions

BIOLOGICAL

Licensed seasonal influenza vaccine

20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine

Sponsors & Collaborators

  • Optimal Health Research

    collaborator OTHER

  • Altimmune, Inc.

    lead INDUSTRY

Principal Investigators

  • Stephan Bart, MD · Optimal Health Research

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-08
Primary Completion
2017-11-21
Completion
2018-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03163342 on ClinicalTrials.gov